Skip to main content
. 2018 Sep 21;36(31):3134–3143. doi: 10.1200/JCO.2018.78.6558

Fig A1.

Fig A1.

Efficacy of lurbinectedin by dose. A waterfall plot shows the maximum variation of target lesions in patients with at least one radiologic tumor assessment in arm A (BRCA1/2) and arm B (BRCA wild-type or unknown status). One patient in arm B had a complete response in target lesions but not in nontarget lesions (objective response was then partial). (*) Confirmed response. (†) Patients with BRCA2 mutation. FD, flat dose; PR, partial response; PD, disease progression.